Related Experiment Video
Updated: May 27, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Association between serum fibroblast growth factor 21 and diabetic nephropathy
Wei-Xia Jian1, Wen-Hui Peng, Jie Jin
1Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Abstract:
Fibroblast growth factor 21 (FGF-21) is a new metabolic regulator with beneficial effects on lipid and glucose metabolism in animal models of diabetes mellitus. The aim of this study was to explore the relationship between FGF-21 and diabetic nephropathy in humans. Serum FGF-21 levels were determined in groups of control (n = 50) and type 2 diabetes mellitus (T2DM) patients with normoalbuminuria (n = 158), microalbuminuria (n = 68), and macroalbuminuria (n = 38) using enzyme-linked immunosorbent assay. Multiple linear regression models were used to analyze the associations between FGF-21 or other biomedical indices and urinary albumin excretion (UAE). Median serum FGF-21 levels were increased in T2DM patients compared with nondiabetic controls and were significantly higher in patients of higher UAE group. In groups of control and T2DM patients with normoalbuminuria, microalbuminuria, and macroalbuminuria, median serum (interquartile range) FGF-21 levels were 467.89 (294.59-519.56), 492.30 (354.59-640.42), 595.01 (480.49-792.31), and 665.20 (448.68-829.75) ng/L (P < .001), respectively. After adjustment for the confounders, FGF-21, fasting plasma glucose, and high-density lipoprotein cholesterol levels were found to be independently associated with UAE in diabetic patients. Serum FGF-21 level is independently correlated with UAE in T2DM patients, indicating that circulating FGF-21 may be involved in diabetic nephropathy.
Insights
Fibroblast growth factor 21 (FGF-21) is linked to diabetic nephropathy. Higher FGF-21 levels correlate with increased urinary albumin excretion in type 2 diabetes patients, suggesting its involvement in kidney damage.
Area of Science:
- Endocrinology and Metabolism
- Nephrology
- Biochemistry
Background:
- Fibroblast growth factor 21 (FGF-21) is recognized as a metabolic regulator with demonstrated benefits in animal models of diabetes.
- Diabetic nephropathy is a significant complication of diabetes mellitus, characterized by kidney damage and albuminuria.
Purpose of the Study:
- To investigate the association between serum FGF-21 levels and diabetic nephropathy in human subjects.
- To determine if FGF-21 is independently correlated with urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus (T2DM).
Main Methods:
- Serum FGF-21 levels were measured using enzyme-linked immunosorbent assay (ELISA) in control subjects and T2DM patients across different stages of albuminuria (normoalbuminuria, microalbuminuria, macroalbuminuria).
- Multiple linear regression models were employed to analyze the relationship between FGF-21, other biomedical indices, and UAE, adjusting for potential confounders.
Main Results:
- Median serum FGF-21 levels were significantly elevated in T2DM patients compared to controls.
- Serum FGF-21 levels showed a positive correlation with the severity of albuminuria, being highest in the macroalbuminuria group.
- FGF-21, fasting plasma glucose, and high-density lipoprotein cholesterol were independently associated with UAE in T2DM patients after confounder adjustment.
Conclusions:
- Circulating FGF-21 levels are independently correlated with urinary albumin excretion in type 2 diabetes mellitus patients.
- These findings suggest that FGF-21 may play a role in the pathogenesis of diabetic nephropathy.
Related Concept Videos
Diabetic Nephropathy
Diabetic Retinopathy
Serum Studies: Renal Function Tests
Nephrotic Syndrome I : Introduction
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Nephrotic Syndrome II : Assessment and Medical Management
